Cyteir Therapeutics Inc (CYT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2014 | 12-2013 | 12-2012 | 12-2011 | 12-2010 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 153,800 | 173,900 | 177,000 | 189,000 | 175,100 |
| Depreciation Amortization | 81,600 | 75,200 | 72,700 | 53,700 | 46,400 |
| Income taxes - deferred | -8,700 | 23,500 | -39,600 | -9,900 | -8,700 |
| Accounts receivable | -37,600 | 13,600 | -9,000 | -44,200 | -26,000 |
| Accounts payable and accrued liabilities | 29,200 | 4,200 | -1,700 | 26,900 | 29,100 |
| Other Working Capital | -85,300 | -46,400 | 41,300 | -49,200 | -52,100 |
| Other Operating Activity | 130,400 | -213,400 | 73,000 | 45,500 | 115,000 |
| Operating Cash Flow | $263,400 | $30,600 | $313,700 | $211,800 | $278,800 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -220,800 | -304,900 | -145,300 | -78,900 | -81,500 |
| Net Acquisitions | N/A | N/A | -449,300 | N/A | N/A |
| Other Investing Activity | 0 | 1,017,000 | 84,700 | 121,200 | -44,000 |
| Investing Cash Flow | $-220,800 | $712,100 | $-509,900 | $42,300 | $-125,500 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 0 | 2,200 | -500 | -2,800 | -4,900 |
| Debt Issued | 251,400 | 634,100 | 318,100 | 0 | 0 |
| Debt Repayment | -246,400 | -658,200 | -268,400 | -5,900 | -34,300 |
| Common Stock Issued | 15,400 | 23,500 | 28,000 | 8,100 | 20,500 |
| Common Stock Repurchased | -50,000 | -750,100 | -99,900 | -196,100 | 0 |
| Dividend Paid | -26,900 | -21,500 | -25,900 | -27,100 | -3,800 |
| Other Financing Activity | 7,900 | 5,500 | 4,600 | 12,300 | -11,100 |
| Financing Cash Flow | $-48,600 | $-764,500 | $-44,000 | $-211,500 | $-33,600 |
| Exchange Rate Effect | -11,900 | -5,700 | 3,700 | -10,100 | 1,900 |
| Beginning Cash Position | 151,800 | 179,300 | 415,800 | 383,300 | 261,700 |
| End Cash Position | 133,900 | 151,800 | 179,300 | 415,800 | 383,300 |
| Net Cash Flow | $-17,900 | $-27,500 | $-236,500 | $32,500 | $121,600 |
| Free Cash Flow | |||||
| Operating Cash Flow | 263,400 | 30,600 | 313,700 | 211,800 | 278,800 |
| Capital Expenditure | -220,800 | -304,900 | -145,300 | -78,900 | -81,500 |
| Free Cash Flow | 42,600 | -274,300 | 168,400 | 132,900 | 197,300 |